LU92241I2 - Combinaison de la protéine de fusion NHBA du groupe B de Neisseria meningitidis et de la protéine defusion fHbp du groupe B de Neisseria meningitidis - Google Patents
Combinaison de la protéine de fusion NHBA du groupe B de Neisseria meningitidis et de la protéine defusion fHbp du groupe B de Neisseria meningitidisInfo
- Publication number
- LU92241I2 LU92241I2 LU92241C LU92241C LU92241I2 LU 92241 I2 LU92241 I2 LU 92241I2 LU 92241 C LU92241 C LU 92241C LU 92241 C LU92241 C LU 92241C LU 92241 I2 LU92241 I2 LU 92241I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- protein
- group
- neisseria meningitidis
- antigens
- defusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0223741A GB0223741D0 (en) | 2002-10-11 | 2002-10-11 | Composition with five meningococcal antigens |
GB0305831A GB0305831D0 (en) | 2003-03-13 | 2003-03-13 | Broad protection meningococcal vaccines |
GB0309115A GB0309115D0 (en) | 2003-04-22 | 2003-04-22 | Broad protection meningococcal vaccines |
PCT/IB2003/004848 WO2004032958A1 (fr) | 2002-10-11 | 2003-10-02 | Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92241I2 true LU92241I2 (fr) | 2013-09-04 |
Family
ID=32096623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92241C LU92241I2 (fr) | 2002-10-11 | 2013-07-04 | Combinaison de la protéine de fusion NHBA du groupe B de Neisseria meningitidis et de la protéine defusion fHbp du groupe B de Neisseria meningitidis |
Country Status (22)
Country | Link |
---|---|
US (2) | US8663656B2 (fr) |
EP (3) | EP2351579B1 (fr) |
JP (4) | JP4697706B2 (fr) |
CN (1) | CN1809380B (fr) |
AT (1) | ATE492288T1 (fr) |
AU (1) | AU2003274511B2 (fr) |
BE (1) | BE2013C042I2 (fr) |
BR (1) | BRPI0315228A8 (fr) |
CA (1) | CA2501812C (fr) |
CY (4) | CY1111341T1 (fr) |
DE (1) | DE60335477D1 (fr) |
DK (3) | DK2353608T3 (fr) |
ES (2) | ES2608048T3 (fr) |
FR (1) | FR13C0040I2 (fr) |
HU (3) | HUE047780T2 (fr) |
LU (1) | LU92241I2 (fr) |
MX (1) | MXPA05003863A (fr) |
NL (1) | NL300604I2 (fr) |
NZ (1) | NZ562998A (fr) |
PT (3) | PT2353608T (fr) |
SI (3) | SI2351579T1 (fr) |
WO (1) | WO2004032958A1 (fr) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2304065T3 (es) | 1998-05-01 | 2008-09-01 | Novartis Vaccines And Diagnostics, Inc. | Antigenos y composiciones de neisseria meningitidis. |
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
US10967045B2 (en) * | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
NZ581940A (en) | 1999-04-30 | 2011-07-29 | Novartis Vaccines & Diagnostic | Conserved neisserial antigens |
AU783894B2 (en) * | 1999-05-19 | 2005-12-22 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
RU2281956C2 (ru) | 1999-10-29 | 2006-08-20 | Чирон С.Р.Л. | Антигенные пептиды neisseria |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
DK2289545T3 (en) * | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
CN100473663C (zh) | 2000-02-28 | 2009-04-01 | 启龙股份公司 | 奈瑟球菌蛋白质的异源表达 |
CA2416137C (fr) * | 2000-07-27 | 2013-01-29 | Dan Granoff | Vaccins pour protection a large spectre contre les maladies causees par neisseria meningitidis |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
JP4592284B2 (ja) * | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 髄膜炎菌付着因子 |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
AU2003215316A1 (en) * | 2002-02-20 | 2003-09-09 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
JP2006500963A (ja) * | 2002-08-02 | 2006-01-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
AU2003274511B2 (en) | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004067030A2 (fr) | 2003-01-30 | 2004-08-12 | Chiron Srl | Vaccins injectables contre les multiples serogroupes du meningocoque |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
ES2397923T3 (es) | 2003-10-02 | 2013-03-12 | Novartis Ag | Vacunas líquidas para múltiples serogrupos meningocócicos |
AU2011224064A1 (en) * | 2003-10-02 | 2011-10-06 | Novartis Vaccines And Diagnostics S.R.L. | Liquid vaccines for multiple meningococcal serogroups |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
DK1740217T3 (da) | 2004-04-30 | 2011-09-26 | Novartis Ag | Meningokok-konjugat-vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
GB0419846D0 (en) * | 2004-09-07 | 2004-10-13 | Chiron Srl | Vaccine adjuvants for saccharides |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP2682126B1 (fr) | 2005-01-27 | 2016-11-23 | Children's Hospital & Research Center at Oakland | Vaccins à vésicule à base de GNA1870 pour protection spectrale élargie contre les maladies causées par Neisseria Meningitidis |
AU2006214064B2 (en) | 2005-02-18 | 2012-04-26 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
MX291624B (es) | 2005-02-18 | 2011-11-04 | Novartis Vaccines & Diagnostic | Inmunogenos de escherichia coli uropatogenica. |
MX2007016403A (es) | 2005-06-27 | 2008-03-07 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
WO2007066226A2 (fr) * | 2005-12-06 | 2007-06-14 | Universita Degli Studi Di Padova | Methodes et compositions relatives a des adhesines servant d'adjuvants |
JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
CA2695467A1 (fr) * | 2007-08-02 | 2009-03-26 | Children's Hospital & Research Center At Oakland | Vaccins vesiculaires a base de fhbp et de lpxl1 pour une protection a large spectre contre les maladies a neisseria meningitidis |
PT2200642E (pt) | 2007-10-19 | 2012-05-30 | Novartis Ag | Formulações de vacinas meningocócicas |
CA2716212A1 (fr) | 2008-02-21 | 2009-08-27 | Novartis Ag | Polypeptides fhbp a meningocoques |
PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
US20100105875A1 (en) * | 2008-06-09 | 2010-04-29 | Maria Scarselli | Antibodies against neisserial factor H binding protein |
IT1394288B1 (it) * | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
US20100189737A1 (en) | 2008-12-17 | 2010-07-29 | Arico Beatrice | Meningococcal vaccines including hemoglobin receptor |
JP5668049B2 (ja) | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
CA2756522C (fr) | 2009-03-24 | 2018-06-26 | Novartis Ag | Proteine de liaison du facteur h meningococcique utilisee comme adjuvant |
WO2010144734A1 (fr) | 2009-06-10 | 2010-12-16 | Novartis Ag | Vaccins contenant de la benzonaphtyridine |
ES2596653T3 (es) | 2009-06-16 | 2017-01-11 | Glaxosmithkline Biologicals Sa | Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento |
JP2013502918A (ja) * | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | 髄膜炎菌fHBP配列を含むハイブリッドポリペプチド |
NZ598459A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
US20130022639A1 (en) | 2009-09-30 | 2013-01-24 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
EP2493499A1 (fr) | 2009-10-27 | 2012-09-05 | Novartis AG | Polypeptides fhbp méningococciques modifiés |
WO2011057148A1 (fr) | 2009-11-05 | 2011-05-12 | Irm Llc | Composés et compositions permettant de moduler l'activité des tlr-7 |
AU2010339921B2 (en) | 2009-12-15 | 2016-08-11 | Glaxosmithkline Biologicals S.A. | Homogeneous suspension of immunopotentiating compounds and uses thereof |
JP2013522287A (ja) | 2010-03-18 | 2013-06-13 | ノバルティス アーゲー | 血清群b髄膜炎菌のためのアジュバント添加ワクチン |
WO2011119759A1 (fr) | 2010-03-23 | 2011-09-29 | Irm Llc | Composés (lipopeptides à base de cystéine) et compositions en tant qu'agonistes des tlr2 utilisés pour traiter des infections, inflammations, maladies respiratoires entre autres |
EP3327028B1 (fr) | 2010-03-30 | 2022-03-16 | Children's Hospital & Research Center at Oakland | Protéines de liaison du facteur h (fhbp) avec des propriétés altérées et leurs procédés d'utilisation |
WO2011149564A1 (fr) | 2010-05-28 | 2011-12-01 | Tetris Online, Inc. | Infrastructure de jeu informatique asynchrone hybride interactif |
US10478483B2 (en) | 2010-06-25 | 2019-11-19 | Glaxosmithkline Biologicals Sa | Combinations of meningococcal factor H binding proteins |
TWI503411B (zh) * | 2010-08-11 | 2015-10-11 | Nat Health Research Institutes | B群腦膜炎球菌次單位疫苗之製造及純化 |
RU2580620C2 (ru) | 2010-08-23 | 2016-04-10 | ВАЙЕТ ЭлЭлСи | СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086 |
ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
ES2744471T3 (es) | 2010-09-04 | 2020-02-25 | Glaxosmithkline Biologicals Sa | Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico |
GB201015132D0 (en) * | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
AU2011300418B2 (en) * | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
BR112013022397A2 (pt) | 2011-03-02 | 2017-09-26 | Derek OHagan | vacinas combinadas com doses menores de antígeno e/ou adjuvante |
PL2822947T3 (pl) | 2012-03-07 | 2017-01-31 | Glaxosmithkline Biologicals Sa | Sole argininowe agonisty TLR7 |
AU2013229432A1 (en) | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MY198910A (en) | 2012-03-09 | 2023-10-02 | Pfizer | Neisseria meningitidis compositions and methods thereof |
JP2015521595A (ja) | 2012-06-14 | 2015-07-30 | ノバルティス アーゲー | 血清群x髄膜炎菌のためのワクチン |
CN104736563A (zh) | 2012-07-27 | 2015-06-24 | 国家健康与医学研究院 | Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附 |
RU2015106930A (ru) | 2012-09-06 | 2016-10-20 | Новартис Аг | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
EP2964665B1 (fr) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Polypeptides immunogènes de fusion |
EA201690056A8 (ru) | 2013-08-02 | 2017-07-31 | Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд | ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
SG11201606478YA (en) | 2014-02-28 | 2016-09-29 | Glaxosmithkline Biolog Sa | Modified meningococcal fhbp polypeptides |
WO2016014719A1 (fr) | 2014-07-23 | 2016-01-28 | Children's Hospital & Research Center Oakland | Variants de protéines de liaison au facteur h et procédés d'utilisation de ceux-ci |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
EP3298031B1 (fr) | 2015-05-18 | 2020-10-21 | BiOMVis Srl | Compositions immunogènes comprenant des vesicules de membrane externe bacteriennes et leur utilisation |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
CN108017688B (zh) * | 2017-12-01 | 2020-07-28 | 北京民海生物科技有限公司 | 一种目的蛋白的纯化方法 |
EP4119570A4 (fr) * | 2020-03-11 | 2023-10-11 | Anygen Co., Ltd. | Composition anti-diabète et anti-obésité comprenant un nouveau composé |
EP4169513A1 (fr) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Composition d'adjuvant comprenant des agonistes du sting |
GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4239746A (en) * | 1973-06-30 | 1980-12-16 | Dezso Istvan Bartos | Complement fixation test employing reactants in a disposable package |
US4239749A (en) | 1979-09-27 | 1980-12-16 | United States Of America | Neisseria gonorrhoeae vaccine |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US20020146764A1 (en) * | 1985-03-28 | 2002-10-10 | Chiron Corporation | Expression using fused genes providing for protein product |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
DE3622221A1 (de) * | 1986-07-02 | 1988-01-14 | Max Planck Gesellschaft | Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen |
EP0273116A3 (fr) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Polypeptides des gonocoques et des méningocoques, vaccins et tests |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
JPH04500203A (ja) | 1988-08-25 | 1992-01-16 | ザ リポソーム カンパニー,インコーポレイテッド | インフルエンザワクチンおよび新規なアジュバント |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
NL8803111A (nl) | 1988-12-19 | 1990-07-16 | Nederlanden Staat | Multivalent meningococcen klasse i buitenmembraaneiwit vaccin. |
AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
CA2006700A1 (fr) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
CU22302A1 (es) * | 1990-09-07 | 1995-01-31 | Cigb | Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales |
IE912559A1 (en) | 1990-07-19 | 1992-01-29 | Merck & Co Inc | The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
ES2127217T3 (es) | 1991-03-14 | 1999-04-16 | Imclone Systems Inc | Epitopos de porina hibridos de recombinacion. |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
DE69423383T2 (de) | 1993-05-13 | 2000-08-24 | American Cyanamid Co | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken |
US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
KR100376361B1 (ko) | 1993-09-22 | 2003-07-18 | 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 | 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법 |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
FR2720408B1 (fr) | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US6287574B1 (en) * | 1995-03-17 | 2001-09-11 | Biochem Pharma Inc. | Proteinase K resistant surface protein of neisseria meningitidis |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
FR2734484B1 (fr) | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
ATE400295T1 (de) | 1995-06-07 | 2008-07-15 | Glaxosmithkline Biolog Sa | Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein |
CN1146444C (zh) | 1995-06-23 | 2004-04-21 | 史密斯克莱·比奇曼生物公司 | 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物 |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
PT854729E (pt) * | 1995-09-18 | 2004-08-31 | Us Army Med Res Mat Com Usamrm | Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente |
FR2739624B1 (fr) | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | Nouvelle sous-unite tbp2 de neisseria meningitidis |
EP0877816A1 (fr) | 1996-02-01 | 1998-11-18 | North American Vaccine, Inc. | Expression de la proteine de la membrane exterieure de neisseria meningitidis du groupe b (mb3) a partir de levures et de vaccins |
FR2751000B1 (fr) | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
US6472518B1 (en) | 1996-10-24 | 2002-10-29 | Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services | Invasion associated genes from Neisseria meningitidis serogroup B |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
EP1279401B1 (fr) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Emulsions du type huile-dans-l'eau contenant des saponines |
AU9363798A (en) | 1997-11-06 | 1999-05-31 | Chiron S.P.A. | Neisserial antigens |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
CA2317815A1 (fr) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Antigenes du $i(neisseria meningitidis) |
NZ338004A (en) | 1998-01-30 | 2001-08-31 | Suntory Ltd | Process for producing peptide with glucagon like peptide-1 (GLP-1) activity by incorporating a protective and helper component to facilitate purification |
IL137809A0 (en) | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
ES2304065T3 (es) * | 1998-05-01 | 2008-09-01 | Novartis Vaccines And Diagnostics, Inc. | Antigenos y composiciones de neisseria meningitidis. |
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
GB9810276D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
US6248329B1 (en) | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
GB9818004D0 (en) | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
EP1109576B1 (fr) | 1998-08-19 | 2009-10-21 | Baxter Healthcare SA | Conjugue de proteine-polysaccharide immunogene a liaison beta-propionamido, utile comme vaccin etabli au moyen d'un polysaccharide n-acryloyle |
AU1202200A (en) * | 1998-10-09 | 2000-05-01 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
PT1126876E (pt) | 1998-10-16 | 2007-04-30 | Glaxosmithkline Biolog Sa | Sistemas adjuvantes e vacinas |
DK1535928T3 (da) | 1998-10-22 | 2008-10-20 | Univ Montana | Vaccinesammensætninger indeholdende Omp85-proteiner af Neisseria gonorrhoeae og Neisseria meningitidis |
US6610306B2 (en) * | 1998-10-22 | 2003-08-26 | The University Of Montana | OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof |
US20030215469A1 (en) * | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
ES2228454T3 (es) | 1999-02-26 | 2005-04-16 | Chiron S.R.L. | Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg. |
EP1034792A1 (fr) | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Administration par voie intranasale de vaccins à base de polyosides de Pneumococcus |
EP1880735A3 (fr) | 1999-03-19 | 2008-03-12 | GlaxoSmithKline Biologicals S.A. | Vaccin |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
NZ581940A (en) * | 1999-04-30 | 2011-07-29 | Novartis Vaccines & Diagnostic | Conserved neisserial antigens |
BR0010361A (pt) | 1999-04-30 | 2003-06-10 | Chiron Corp | Seq ências genÈmicas de neisseria e uso destas |
GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
AU783894B2 (en) | 1999-05-19 | 2005-12-22 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
CO5200838A1 (es) | 1999-09-24 | 2002-09-27 | Smithkline Beecham Corp | Vacunas |
IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
RU2281956C2 (ru) | 1999-10-29 | 2006-08-20 | Чирон С.Р.Л. | Антигенные пептиды neisseria |
RU2002117308A (ru) * | 1999-11-29 | 2004-03-10 | Чирон Спа (It) | 85 кДа АНТИГЕН NEISSERIA |
DK2289545T3 (en) * | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
CA2396871A1 (fr) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Acides nucleiques immunostimulateurs permettant d'induire une reponse immunitaire th2 |
KR100698561B1 (ko) | 2000-01-25 | 2007-03-21 | 더 유니버서티 어브 퀸슬랜드 | Neisseria Meningitidis 표면 항원ΝhhΑ의 보존 부위를 포함하는 단백질 |
CN100473663C (zh) * | 2000-02-28 | 2009-04-01 | 启龙股份公司 | 奈瑟球菌蛋白质的异源表达 |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
CA2783274C (fr) | 2000-06-29 | 2018-08-07 | Glaxosmithkline Biologicals S.A. | Composition de vaccin multivalent a dose reduite d'haemophilus influenza de type b |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
GB0108024D0 (en) * | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
EP1409013B1 (fr) | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccins comprenant des adjuvants aluminium et histidine |
JP4592284B2 (ja) | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 髄膜炎菌付着因子 |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
WO2003024481A2 (fr) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | Emballage de substances immunnostimulatrices dans des particules de type virus : procede de preparation et utilisation correspondants |
US20030091593A1 (en) | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US7838015B2 (en) * | 2001-10-03 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
WO2003035836A2 (fr) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5' |
MXPA04009339A (es) | 2002-03-26 | 2005-01-25 | Chiron Srl | Sacaridos modificados que tienen estabilidad mejorada en agua. |
JP2006500963A (ja) * | 2002-08-02 | 2006-01-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
AU2003274511B2 (en) | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004067030A2 (fr) | 2003-01-30 | 2004-08-12 | Chiron Srl | Vaccins injectables contre les multiples serogroupes du meningocoque |
GB0315021D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
ES2397923T3 (es) | 2003-10-02 | 2013-03-12 | Novartis Ag | Vacunas líquidas para múltiples serogrupos meningocócicos |
GB0323103D0 (en) * | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0409748D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
GB0410866D0 (en) * | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
NZ573931A (en) * | 2006-06-29 | 2012-03-30 | Craig J Venter Inst Inc | Polypeptides from neisseria meningitidis |
CA2716212A1 (fr) | 2008-02-21 | 2009-08-27 | Novartis Ag | Polypeptides fhbp a meningocoques |
GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
-
2003
- 2003-10-02 AU AU2003274511A patent/AU2003274511B2/en active Active
- 2003-10-02 EP EP10181277.4A patent/EP2351579B1/fr not_active Expired - Lifetime
- 2003-10-02 CN CN200380105896XA patent/CN1809380B/zh not_active Expired - Lifetime
- 2003-10-02 SI SI200332505A patent/SI2351579T1/sl unknown
- 2003-10-02 DK DK10181233.7T patent/DK2353608T3/da active
- 2003-10-02 SI SI200331962T patent/SI1549338T1/sl unknown
- 2003-10-02 WO PCT/IB2003/004848 patent/WO2004032958A1/fr active Search and Examination
- 2003-10-02 DK DK10181277.4T patent/DK2351579T3/en active
- 2003-10-02 EP EP03758486A patent/EP1549338B1/fr not_active Expired - Lifetime
- 2003-10-02 US US10/530,753 patent/US8663656B2/en active Active
- 2003-10-02 ES ES10181277.4T patent/ES2608048T3/es not_active Expired - Lifetime
- 2003-10-02 AT AT03758486T patent/ATE492288T1/de active
- 2003-10-02 NZ NZ562998A patent/NZ562998A/xx not_active IP Right Cessation
- 2003-10-02 DE DE60335477T patent/DE60335477D1/de not_active Expired - Lifetime
- 2003-10-02 JP JP2005501008A patent/JP4697706B2/ja not_active Expired - Lifetime
- 2003-10-02 HU HUE10181233A patent/HUE047780T2/hu unknown
- 2003-10-02 SI SI200332606T patent/SI2353608T1/sl unknown
- 2003-10-02 CA CA2501812A patent/CA2501812C/fr not_active Expired - Lifetime
- 2003-10-02 MX MXPA05003863A patent/MXPA05003863A/es active IP Right Grant
- 2003-10-02 BR BRPI0315228A patent/BRPI0315228A8/pt not_active Application Discontinuation
- 2003-10-02 DK DK03758486.9T patent/DK1549338T3/da active
- 2003-10-02 PT PT101812337T patent/PT2353608T/pt unknown
- 2003-10-02 HU HUE10181277A patent/HUE031886T2/en unknown
- 2003-10-02 ES ES10181233T patent/ES2775098T3/es not_active Expired - Lifetime
- 2003-10-02 PT PT03758486T patent/PT1549338E/pt unknown
- 2003-10-02 EP EP10181233.7A patent/EP2353608B1/fr not_active Expired - Lifetime
- 2003-10-02 PT PT101812774T patent/PT2351579T/pt unknown
-
2010
- 2010-04-07 JP JP2010089061A patent/JP5705450B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-15 CY CY20111100292T patent/CY1111341T1/el unknown
-
2012
- 2012-09-21 JP JP2012207826A patent/JP2013006868A/ja not_active Withdrawn
-
2013
- 2013-06-27 BE BE2013C042C patent/BE2013C042I2/fr unknown
- 2013-07-03 CY CY2013026C patent/CY2013026I1/el unknown
- 2013-07-04 LU LU92241C patent/LU92241I2/fr unknown
- 2013-07-08 HU HUS1300030C patent/HUS1300030I1/hu unknown
- 2013-07-11 FR FR13C0040C patent/FR13C0040I2/fr active Active
- 2013-07-15 NL NL300604C patent/NL300604I2/nl unknown
-
2014
- 2014-02-12 US US14/178,970 patent/US20140212449A1/en not_active Abandoned
- 2014-08-13 JP JP2014164678A patent/JP2014218515A/ja not_active Withdrawn
-
2016
- 2016-12-13 CY CY20161101282T patent/CY1118606T1/el unknown
-
2020
- 2020-03-16 CY CY20201100227T patent/CY1122869T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92241I2 (fr) | Combinaison de la protéine de fusion NHBA du groupe B de Neisseria meningitidis et de la protéine defusion fHbp du groupe B de Neisseria meningitidis | |
RU2378009C2 (ru) | Иммунизация против менингококков серогруппы y с помощью белков | |
HUP0302999A2 (hu) | Multivalens, meningokokkusz-eredetû poliszaccharid és fehérje konjugátumát tartalmazó vakcina | |
HUP0002475A2 (hu) | Módosított immunogén pneumolizinkészítmények mint vakcinák | |
GB0130123D0 (en) | Outer membrane vesicle vaccine and its preparation | |
NO20050010L (no) | Vaksineblandinger omfattende transferrin-bindende protein og HSF fra gram-negative bakterier | |
NO20071609L (no) | Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker | |
BR0113822A (pt) | Vacina | |
ES2157993T3 (es) | Benzoilguanidinas, su preparacion y su uso en medicamentos. | |
DK1741784T3 (da) | 85kDa-antigen fra neisseria | |
DK2054431T3 (da) | Konformere af bakterielle adhæsiner | |
NO964413D0 (no) | Gruppe A streptokokkisk polysakkarid, immunogene blandinger derav samt anvendelse derav | |
ATE544470T1 (de) | Immuntherapeutische methoden und zusammensetzungen | |
BRPI0411875A (pt) | método de imunização contra os sorogrupos a e c de neisseria meningitidis | |
Maeba et al. | Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis | |
NO995481L (no) | Glykokonjugater av 20 (S)-camptothecin | |
Zhu et al. | Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model | |
WO2005117956A3 (fr) | Vaccin | |
WO2002030458A8 (fr) | Composition | |
CA2535214C (fr) | Compositions vaccinales a base de gangliosides a administration par voie sous-cutanee | |
Norheim et al. | Prevention of serogroup A, C and W135 meningococcal disease in Africa with outer membrane vesicle vaccines | |
WO2005023295A3 (fr) | Peptides immunodominants traites naturellement derives de la proteine a des porines de neisseria meningitidis et leur utilisation |